This is Archived Content

This content is available for historical purposes only. It may not reflect the current state of science or language from the National Institute on Drug Abuse (NIDA). Find the latest information on substance use, health, and NIDA research at

Cite this article

NIDA. (2013, November 1). Gene variant may predict whether a person will benefit from nicotine replacement therapies. Retrieved from

press ctrl+c to copy

Science Spotlight

November 01, 2013

Unhappy face on cigarettes

NIH-funded research shows that differences in the CYP2A6 gene -- which controls in part how fast nicotine is metabolized -- can predict whether nicotine replacement therapies (nicotine lozenge and/or nicotine patch) will be effective in helping a person quit smoking. The effectiveness of buproprion, a non-nicotine based medication often prescribed to quit smoking, was not affected by differences in this gene.

This study adds to previous findings with the CHRNA5 gene, showing that screening for genetic variation may better guide personalized treatments to quit smoking.

The study was partially funded by NIDA, NCI, NHGRI, NCATS, and NIMH. For a copy of the study, published online Sept 11, go to

For more information, contact the NIDA press office at or 301-443-6245.